title: Benefits of adjunctive moxifloxacin in generalized aggressive periodontitis: a subgroup analyses in Aggregatibacter actinomycetemcomitans-positive/negative patients from a clinical trial.
abstract: OBJECTIVE
  The aim of the present study was to evaluate the influence of the baseline detection of Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) on the clinical outcomes of moxifloxacin (MOX) as an adjunct to full-mouth scaling and root planing (SRP) in generalized aggressive periodontitis (GAgP).
  
  
  METHODS
  Forty patients were randomly distributed to two therapy protocols: SRP + placebo or SRP combined with MOX. A. actinomycetemcomitans was detected using culture methods. The significance of the treatment option (MOX or SRP + placebo) on the dependent variables (probing depth [PD] and clinical attachment level [CAL]), considering the interaction with the baseline detection of A. actinomycetemcomitans, was estimated.
  
  
  RESULTS
  MOX therapy led to a higher significant PD reduction and CAL gain in A. actinomycetemcomitans-positive patients at baseline. In A. actinomycetemcomitans-positive patients, the reduction of sites ≥5 mm was higher in the MOX group. A. actinomycetemcomitans was not present in sites with PD ≥6 mm in the MOX group. The interactions of A. actinomycetemcomitans and MOX were significantly associated with CAL gain and PD reduction at 6 months.
  
  
  CONCLUSIONS
  Adjunctive MOX trended toward better clinical responses in A. actinomycetemcomitans-positive patients at baseline. These results suggest that A. actinomycetemcomitans at baseline might modify the effect of adjunctive MOX in GAgP.
authors.affiliation: Biomedical Stomatology Research Group, Universidad de Antioquia, Medellín, Colombia.
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Ardila
authors.affiliation: Biomedical Stomatology Research Group, Universidad de Antioquia, Medellín, Colombia.
authors.forename: Isabel C
authors.initials: IC
authors.lastname: Guzmán
mesh_terms: D016976:Aggregatibacter actinomycetemcomitans / Q000302:isolation & purification*; D010520:Aggressive Periodontitis / Q000188:drug therapy* / Q000382:microbiology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D012534:Dental Scaling; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D016014:Linear Models; D000077266:Moxifloxacin; D016871:Pasteurellaceae Infections / Q000188:drug therapy*; D016745:Root Planing
chemical_list: D024841:Fluoroquinolones; D000077266:Moxifloxacin
keywords: 
  Aggregatibacter actinomycetemcomitans
  ; clinical trial; generalized aggressive periodontitis; moxifloxacin; scaling and root planing